Why Enclomiphene Doesn't Work for Every Man

Published 10/21/2026

Key Takeaways

Enclomiphene raises testosterone by increasing LH and FSH, so it needs testes capable of responding to that increase.
It is not effective for men with a diagnosed primary hypogonadism, where LH and FSH are already elevated.
Because it works through the body's own axis, it does not suppress sperm production the way replacement testosterone does.
Enclomiphene is supplied as a compounded drug product. Compounded drugs are not approved by the FDA and do not undergo FDA review for safety, effectiveness, or quality.
A reversible cause such as opioid use, untreated sleep apnoea, or obesity may need addressing before any prescription is appropriate.

Most articles about a treatment are written to persuade you that it will work. This one is about the cases where it will not, because that is more useful information and it is harder to find.

Enclomiphene has a narrow and well-described mechanism. A narrow mechanism means a defined population, and being outside that population is not a dosing problem.

What It Actually Does

Enclomiphene is a selective estrogen receptor modulator. It blocks estrogen feedback at the hypothalamus and pituitary, which lifts the brake on gonadotropin release. LH and FSH rise, and the testes respond by producing more testosterone.

The important word is respond. Enclomiphene does not supply testosterone. It asks your body to supply more, which only works if your body is able to comply.

In a published pharmacodynamic study, men taking 25 mg saw LH increase from 5.3 to 11.9 mIU/mL and FSH from 9.4 to 14.9 mIU/mL, with total testosterone rising over the same period.

Who It Does Not Help

Men with primary hypogonadism. This is the clearest exclusion. In primary hypogonadism the testes cannot respond to gonadotropin signalling, and the body has usually already raised LH and FSH in an attempt to compensate. Enclomiphene raises them further, into a system that is not answering. It will not produce a meaningful testosterone response, and it is not effective for men carrying this diagnosis.

Establishing which type you have is a blood test, not a judgement call, which is why a panel including LH and FSH comes before any prescribing conversation.

Men whose low testosterone has a reversible cause that has not been addressed. Obesity, untreated sleep apnoea, prolonged opioid use, significant alcohol intake, and prior anabolic steroid use all suppress the axis. Prescribing into an unaddressed cause treats a symptom and leaves the mechanism running. In several of these cases, resolving the underlying factor improves production without a prescription.

Men whose symptoms are not actually driven by testosterone. Fatigue, low mood, and reduced drive overlap with thyroid dysfunction, iron deficiency, depression, poor sleep quality, and several medications. A full panel exists partly to rule these in or out, because raising testosterone will not fix a problem testosterone was not causing.

Men who do not meet the diagnostic threshold. Guideline practice is to diagnose hypogonadism only in men with both symptoms and consistently low, accurately measured testosterone, confirmed on a repeat morning sample. One borderline result is not that.

Who It Suits Well

The population enclomiphene fits is specific and it is also large.

Men with secondary hypogonadism, where the testes work and the signal is the problem, are the group whose mechanism matches the drug. Within that group, two situations make it a particularly good fit.

Men who want to preserve fertility. This is the clearest practical advantage and it is well documented. Replacement testosterone suppresses the body's own axis, which reduces sperm production. In a direct comparison against transdermal testosterone, no man on testosterone gel had a sperm concentration above 12 million/mL at three months, while no man on enclomiphene fell below 75 million/mL, with a mean of 176 million/mL. Because enclomiphene raises FSH alongside LH, it supports the part of the axis that replacement shuts down.

Men who would rather not manage injections or topical gels. It is a daily oral tablet. For some men that is a preference; for men with young children at home, avoiding transdermal gel and its transfer risk is a practical consideration.

The Regulatory Status, Stated Plainly

This belongs in any honest article on the subject.

Enclomiphene as prescribed in this context is supplied as a compounded drug product. Compounded drugs are not approved by the FDA and do not undergo FDA review or verification for safety, effectiveness, or quality. It requires a prescription, and it requires a clinician who has seen your labs.

That is not an argument against it. Compounded preparations are a normal part of medicine and the published evidence base for enclomiphene in secondary hypogonadism is real. But "not FDA approved" and "unproven" are different statements, and so are "compounded" and "off-label", and you should know which one applies to what you are taking.

What Good Prescribing Looks Like

If a provider is doing this properly, the sequence is not negotiable:

A panel that includes total testosterone, LH, FSH, SHBG, and the markers needed to exclude other causes
A repeat morning measurement to confirm, rather than acting on one number
Classification as primary or secondary, because that determines whether the drug can work
A review of reversible contributors before prescribing
Follow-up bloodwork to confirm the treatment is doing what it is supposed to

A service that skips straight from a questionnaire to a prescription has skipped the step that determines whether the prescription can help you at all.

Frequently Asked Questions

Who should not take enclomiphene?

Men with diagnosed primary hypogonadism, in whom it is not effective, and men whose low testosterone has an unaddressed reversible cause or a non-hormonal explanation. A clinician reviewing a full panel makes this determination.

Why would enclomiphene not work for me?

The most common reason is that the problem is at the testes rather than in the signalling. Enclomiphene raises LH and FSH, which only helps if the testes can respond to them.

Is enclomiphene FDA approved?

No. It is supplied as a compounded drug product, and compounded drugs are not approved by the FDA and do not undergo FDA review for safety, effectiveness, or quality. It requires a prescription and a medical evaluation.

Does enclomiphene affect fertility?

It does not suppress sperm production the way replacement testosterone does, because it raises FSH alongside LH rather than replacing testosterone from outside the body. Published comparisons show markedly different sperm concentrations between the two approaches.

How long before you know if it is working?

Hormonal changes appear within weeks, which is why follow-up bloodwork is scheduled rather than optional. Whether symptoms follow is a separate question your clinician assesses alongside the numbers.

The Bottom Line

Enclomiphene is a good answer to one specific question: what do you do when the testes work and the signal does not. It is not an answer to low testosterone in general, and the test that tells you which situation you are in costs far less than a course of treatment that was never going to help.